Stereotactic Body Radiotherapy in Non-Small Cell Lung Cancer Patients: Assessment of Response and Toxicity at Single İnstitution
Küçük Resim Yok
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objective: The aim of this study is to assess the efficacy and acute toxicity of stereo tactic body radiotherapy (SBRT) for either primary or metastatic masses of lung tumors. Material and Methods: Analysis was performed on 110 lung tumor masses (primarily non-small cell origin, a small proportion was metastatic) patients treated by CyberKnife® in our clinic between February 2010 and July 2015. Doses had been delivered ranged 20–60 Gy, in one to seven once-daily fractions, depending on tumor size and location. Results: The median follow-up duration after SBRT was 29 months (range 14, 75–40 months). The median overall survival (OS) was 31.62 months (95% CI, 24.06–37.93 months). 3-year survival was 42% and 5-year survival was 22%. Conclusion: Lung tumors (primary or metastatic) treated by SBRT had better treat ment response and less toxicity compared with conventional radiotherapy schedules. If available-depending on size and location of the tumor(s) - SBRT is the most afford able; preferable option.
Açıklama
Anahtar Kelimeler
Kaynak
İzmir Göğüs Hastanesi Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
36
Sayı
2